Janux Therapeutics Insider Deals: CEO’s Tax‑Cover Sale Confirms Long‑Term Confidence Amid Sector‑Wide Sell‑Off
Janux insider sell‑to‑cover: CEO Doyle Noel’s routine tax‑cover sale of 4,059 shares at $14.03 shows no shift in strategy, confirming management’s long‑term confidence amid a sector‑wide biotech sell‑off.
3 minutes to read